For research teams searching for a dependable source of gene vectors, Wuhan MiaoLing Biotechnology Co., Ltd. — known in the market as MiaoLing, MiaoLing Bio, or the MiaoLing Plasmid Platform — has built a business model specifically designed to solve two chronic pain points in molecular biology: slow plasmid construction and high custom synthesis costs. Founded on June 12, 2014, and headquartered in the Wuhan National Bio-Industry Base, the company operates a dual-engine system combining a massive ready-stock gene vector bank with custom vector construction services, giving researchers two clear paths depending on urgency and specificity of need.
Overview of MiaoLing Bio's Plasmid Product Portfolio
The company's plasmid offerings fall into distinct product lines, each addressing a different experimental scenario:
- Mammalian Expression Plasmids — a one-stop mammalian expression bank spanning 40+ series (including pCDNA and pCMV) that supports everything from basic expression to inducible systems.
- Lentiviral Plasmids — the pLV3 series with WPRE is engineered to boost viral titers and transduction efficiency for high-titer packaging needs.
- Promoter Reporter Plasmids — built on a Dual-Luciferase System, these serve promoter and miRNA studies with accurate data and internal controls.
- Interferon/Regulation-Related Plasmids (RNAi) — shRNA interference vectors driven by the U6 promoter for efficient knockdown in loss-of-function studies.
- Gene Editing Plasmids (CRISPR/Cas9) — All-in-One vectors that co-express Cas9, sgRNA, and selection markers, ready for immediate genome editing work.
- Adeno-Associated Virus (AAV) Plasmids — featuring tissue-specific promoters that enable liver- or neuron-specific expression for gene therapy research.
- Prokaryotic Expression Plasmids — classic systems such as pET28a and pGEX4T1, optimized for protein preparation.
- CRISPR Libraries — genome-wide coverage that saves researchers the time otherwise spent on library construction.
This breadth is backed by scale: MiaoLing Bio maintains an inventory of more than 150,000 plasmid stocks, described as among the largest in China, with over 150,000 SKUs in its ready-stock plasmid library. The company reports serving over 6,000 institutions nationwide, covering virtually all top universities and research institutes, and exporting to Japan, the USA, India, Russia, and other markets. Annual throughput reaches approximately 120,000 plasmids and 60,000 orders delivered, alongside year-on-year revenue growth of 30–40%.
Ready-Stock Plasmid Advantages
For researchers who need a vector immediately, the ready-stock line is designed around speed without sacrificing quality. Vectors are stored in constant-temperature cold rooms, and online search, order placement, and automated retrieval enable dispatch within 8 hours. Delivery commitments include a same-city 24-hour delivery rate of 90% and a provincial 48-hour delivery rate of 95%, with cold-chain logistics used for out-of-province shipments to preserve plasmid integrity.
Specifications are flexible — customers can choose glycerol stocks, dry-form plasmids, or 100 μg low-endotoxin liquid ready-to-use plasmids — suited to pilot experiments, large-scale virus packaging, or high-throughput screening. Coverage extends beyond common human and mouse vectors to include cattle, pig, chicken, SARS-CoV-2, C. elegans, Drosophila, plants, and other niche species, removing the need for custom design in many cases. Every stock plasmid undergoes full-length sequencing, restriction enzyme digestion, and endotoxin testing, with each shipment including sequence files, vector maps, and QC reports so it is ready for transfection without secondary verification. Because bulk reproduction spreads R&D and production costs, stock plasmids are positioned to be cheaper than the consumable costs of self-construction — a direct saving on grant funds.
Plasmid Customization Options
When a stock vector does not match a specific experimental design, MiaoLing Bio's custom vector construction service allows free combination of vector backbone, fluorescent tags, selection markers, promoters, and multiple cloning sites (MCS), with support for 3×FLAG, HA, MYC, Luc2, mCherry, EGFP, and over 100 elements for complex multi-label experiments. Both traditional double-restriction-enzyme cloning and seamless Gibson assembly are available, supporting long fragments, repetitive sequences, and high-GC difficult-to-amplify genes. Turnaround has been shortened so that fragments ≤1 kb are delivered in as few as 5 working days, while long fragments and multi-sgRNA CRISPR vectors are completed within ≤4 weeks. The standard custom vector delivery cycle overall has been reduced from 7 to 5 working days.
How to Purchase: The Ordering Process
For ready-stock plasmids, the process follows five steps: (1) the customer searches the vector catalog number online and downloads the sequence and map; (2) the order is submitted, and customer service verifies vector type, specification, and intended use; (3) quality control runs an endotoxin assay, agarose gel electrophoresis, and sequence verification; (4) the plasmid is aliquoted, cold-chain packaged, and dispatched within 8 hours; and (5) the shipment arrives with a QC report, vector sequence, and instruction manual.
For custom plasmid construction, the workflow is more detailed: pre-sales technical consultation confirms the vector backbone, gene sequence, tag, resistance, promoter, and cloning strategy; primers are designed and sequences optimized to ease amplification of high-GC and repeat regions; PCR amplification, gel extraction, and purification follow; the vector is linearized via double digestion or Gibson linearization; ligation and transformation into competent cells occur next; colony PCR performs initial positive clone screening; mini-prep plasmid from positive clones undergoes restriction digestion and gel electrophoresis for secondary size verification; full-length sequencing provides final validation to ensure 100% sequence accuracy; after customer confirmation, scale-up culture and preparation of the requested format (glycerol stock, dry powder, or large-prep plasmid) takes place; and finally QC, packaging, and delivery are completed with full experimental documentation.
Before and after purchase, MiaoLing Bio provides free pre-sales technical services, including one-on-one vector selection design, free sgRNA and primer design with off-target risk assessment, and free distribution of vector maps and sequence files. Post-sale, the company commits to acknowledging after-sales issues within 2 hours and resolving routine issues within 24 hours, with quality-related compensation or replacement processed within 48 hours. Guarantees cover free replacement for sequence mismatch, contamination, or endotoxin exceedance, free re-construction for custom vectors with sequencing errors, and proportional refunds or re-packaging if lentivirus titers fall below contract specification.
Market Reputation and Proven Results
MiaoLing Bio's products have been cited in nearly 1,000 SCI papers across oncology, stem cells, gene therapy, and synthetic biology. Long-term institutional relationships illustrate sustained trust: a nearly 10-year collaboration with Wuhan University involving 370+ research groups and cumulative value exceeding RMB 2 million; an 8-year partnership with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, cumulative value over RMB 1 million; and a 10-year relationship with Zhejiang University, cumulative value exceeding RMB 2.5 million. Documented use cases include stable lentiviral cell line construction with the pLV3-CMV series for human SRCAP overexpression, gene knockout support using pX330 and multi-sgRNA vectors such as pLV3-U6-RUVBL1AS1, promoter activity screening with pGL3-Basic or pAxl-Fluc reporter systems, and COVID-19 research support through viral gene vectors including orf1b and pGBWm4092677.
Backed by National High-Tech Enterprise accreditation, ISO9001 quality certification, and a technical team where over 50% of R&D staff hold Master's or Doctoral degrees, MiaoLing Bio positions its combined ready-stock and custom plasmid system as a practical answer for labs that need both speed and precision in their gene vector supply chain.
https://en.miaolingbio.com/
Wuhan MiaoLing Biotechnology Co., Ltd.